Kolexia
Limacher Jean Marc Oncologie médicale
Limacher Jean Marc
Oncologie médicale
Hôpital Louis Pasteur Colmar
Colmar, France
81 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Prédisposition génétique à une maladie Carcinome pulmonaire à petites cellules Carcinomes Tumeurs du sein Tumeurs du foie Néphrocarcinome Carcinome hépatocellulaire

Collaborateurs

Voir plus
Maugard Christine
Maugard Christine
Hôpital Hautepierre, Strasbourg, France
Caron Olivier
Caron Olivier
Gustave-Roussy, Villejuif, France
Hutt Emilie
Hutt Emilie
Hôpital Louis Pasteur Colmar, Colmar, France
Stoppa-Lyonnet Dominique
Stoppa-Lyonnet Dominique
Clcc Institut Curie, Paris, France

Industries

Voir plus
AstraZeneca
9 collaboration(s)
Dernière en 2022
Lilly
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023
A+A
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
COVAR: Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling
Essai Clinique (Institut Curie)   16 janvier 2024
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Essai Clinique (Transgene)   01 août 2023
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
European journal of cancer (Oxford, England : 1990)   11 juillet 2023
Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
European journal of cancer (Oxford, England : 1990)   13 novembre 2022
The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.
Digestive diseases and sciences   31 octobre 2022
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Clinical breast cancer   13 octobre 2022
A novel germline pathogenic variant MET c.3389T>C p.(Leu1130Ser) identified in french population
Abstracts from the 54th European Society of Human Genetics (ESHG) Conference   01 avril 2022
Specific phenotype of germline MET mutations in papillary renal cell carcinoma type 1: about a large french series of 158 patients
Abstracts from the 54th European Society of Human Genetics (ESHG) Conference   01 avril 2022
Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
2021 San Antonio Breast Cancer Symposium   15 février 2022
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Human mutation   19 janvier 2022